Searching On:

Drug:

SAR260301

View:
Expand Collapse SAR260301  - General Description SAR260301 is a PI3K inhibitor with selective ß-isoform inhibitory activity and blocking PI3K- signaling in PTEN-deficient tumor models, both in vitro and in vivo. SAR260301 is a potent PI3K, ß-isoform-selective inhibitor. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.



SAR260301 is a PI3K inhibitor with selective ß-isoform inhibitory activity and blocking PI3K- signaling in PTEN-deficient tumor models, both in vitro and in vivo. SAR260301 is a potent PI3K, ß-isoform-selective inhibitor. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.



Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (D) - Drug
Trial Status: No record found.
Protocol # Title Location Status Match
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
There are currently no clinical trials available for your selection. New clinical trials are being approved every day. Please continue to check back for updates.
Trial Status: No record found.

Share with your Physican

Print information for your Physician.

Print information